Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jan 1;22(1):11-18.
doi: 10.31557/APJCP.2021.22.1.11.

HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis

Tung Nguyen Thanh  1   2 , Bao Song Nguyen Tran  3 , Ai Phuong Hoang Thi  2 , Thang Tran Binh  4 , Thong Ba Nguyen  5 , Tam Le Minh  6 , Quoc Huy Nguyen Vu  6 , Thuan Dang Cong  3
Affiliations
Meta-Analysis

HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis

Tung Nguyen Thanh et al. Asian Pac J Cancer Prev. .

Abstract

ackground: Human epidermal growth factor receptor 2 (HER2) plays an important role in the development and progression of breast cancer. To understand the precise association, this meta-analysis was conducted to estimate the association between HER2Ile655Val single nucleotide polymorphism (SNP) and susceptibility to early-onset breast cancer.

Methods: A comprehensive database retrieval from PubMed, Embase, Web of Science and Google Scholar was pooled to investigate links between the HER2Ile655Val SNP and risk of breast cancer. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to appraise the association under the additive model (Ile vs. Val), dominant model (Val/Val + Ile/Val vs. Ile/Ile), and recessive model (Val/Val vs. Ile/Val + Ile/Ile).

Results: Seventeen relevant studies with 11,749 cases and 8,105 controls were finally included. We found that HER2Ile655Val SNP is associated with an increased risk of breast cancer in an additive and dominant model. In the subgroup analysis with age stratification, a significant association between the HER2 codon 655 SNP and the risk of breast cancer was found in young women in an additive, dominant, and recessive model; conversely, no significant associations were indicated in older women. In the breast cancer subgroup, HER2Ile655Val SNP was significantly associated with younger age women with breast cancer in the dominant model. In contrast, no association between the HER2 codon 655 SNP and age was found in control populations.

Conclusion: Our findings suggest that the Val allele in HER2 codon 655 SNP is strongly associated with breast cancer susceptibility in the young female population and is also significantly associated with younger age in women with breast cancer. HER2Ile655Val SNP might be a susceptibility factor that favours early-onset breast cancer.<br />.

Keywords: Early-onset; HER2Ile655Val; Meta-analysis; Single nucleotide polymorphism; breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The Selection Process of Papers for the Meta-Analysis Study
Figure 2
Figure 2
Association between HER2Ile655Val SNP and Breast Cancer Risk Worldwide. A. Forest plot for the association between HER2Ile655Val SNP and breast cancer risk; B. Funnel plot evaluating publication bias among studies included in the meta-analysis
Figure 3
Figure 3
HER2Ile655Val SNP is Associated with an Increased Breast Cancer Risk in Young Women. A. Forest plot for the association between HER2Ile655Val SNP and breast cancer risk in young women; B. Funnel plot evaluating for publication bias among studies included in the meta-analysis
Figure 4
Figure 4
HER2Ile655Val SNP is Associated with an InCreased Risk of Early-Onset Breast Cancer. A. Forest plot for the association between HER2Ile655Val SNP and an increased risk of early-onset breast cancer; B. Funnel plot evaluating for publication bias among studies included in the meta-analysis
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23:2534–43. - PubMed
    1. Al-Janabi AM, Algenabi AHA, Kamoona TH, et al. Association of HER2 [ILe655Val] gene polymorphism and Breast Cancer Risk in Iraqi females Population. Int J Adv Res. 2015;3:1483–9.
    1. Ameyaw M-M, Tayeb M, Thornton N, et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet. 2002;47:172–5. - PubMed
    1. An Hee J, Haeyoun K, Nam Keun Kim S. Her2 genotype and breast cancer progression in Korean women. Pathol Int. 2005;55:48–52. - PubMed
    1. An HJ, Kim NK, Oh D, et al. Her2 genotype and breast cancer progression in Korean women. Pathol Int. 2005;55:48–52. - PubMed